🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)

Recruitingn/aAges 18 Years - anyAllUniversity Hospital, Montpellier
NCT06287749 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The overall objective of this GUIDE.MRD consortium is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice. Primary objective To confirm that ctDNA analyses performed after PDAC treatment can identify patients with a high risk-of-recurrence. Specifically, the investigators want to determine the association between disease-free survival (DFS) and ctDNA detection status after 1. curative-intended surgery and 2. adjuvant chemotherapy. FRENCH.MRD.PDAC is the French study of the european GUIDE.MRD project

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Pancreatic ductal adenocarcinoma, according to the assessment of the MDT. * Age 18 years or older. * Scheduled for curative intent surgical resection. Exclusion Criteria: * Hereditary pancreatic cancer. * Verified distant metastases. * Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits and/or otherwise considered by the Investigator to be unlikely to complete the study. * Other cancers (excluding prior pancreatic cancer or skin cancer other than melanoma) within 3 years from eligibility screening. * Pregnant or nursing woman, or in childbearing age and not willing to use contraception * Adult subject to a legal protection * Not covered by Health insurance * Patient unable to understand and sign written informed consent.
💊

What it tests

  • Blood sample/Liquid Biopsy
📍

Where

1 site
CHU de Montpellier
Montpellier, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy